CTIX News 1.6500 08/01/2014 04:51:51 Cellceutix Corp (CTIX)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Cellceutix Corp (CTIX) 1.6500 $CTIX

Plague - Pipeline Review, H1 2014
M2 - Wed Jul 30, 2:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xgdb3j/plague_pipeline) has announced the addition of the "Plague - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Plague, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Plague and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Plague - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Plague and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Plague products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Mentioned: - Takeda Pharmaceutical - Summit Corporation - Mucosis - iBio - Cellceutix Corporation For more information visit http://www.researchandmarkets.com/research/xg...e_pipeline

Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Pipeline Review, H1 2014
M2 - Tue Jul 15, 11:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/g486rc/methicillinsuscep) has announced the addition of the "Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - Dainippon Sumitomo Pharma Co., Ltd. - Immtech Pharmaceuticals, Inc. - Cellceutix Corporation - Lytix Biopharma AS - PharmaIN Corporation - ImmuVen, Inc. - Arsanis Biosciences GmbH For more information visit http://www.researchandmarkets.com/research/g4...llinsuscep

Cellceutix Announces Breakthrough in the Formulation of Its Novel Antibiotic Brilacidin(TM), Plans Studies to Treat Diabetic Foot Ulcers
Marketwire - Mon Jul 14, 6:00AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to announce that a significant breakthrough has been made in the formulation of Brilacidin(TM), Cellceutix's lead antibiotic in its portfolio of novel compounds called defensin mimetics. Previously, Brilacidin was stored in a refrigerated state. Cellceutix has stabilized the formulation of Brilacidin so that it is now stable at room temperature. This positions the Company to move forward with the immediate development of Brilacidin for the treatment of infected diabetic foot ulcers. Ophthalmic and otitic formulations will soon follow for ophthalmic and otitis media indications.

Cellceutix Anti-Fungal Compounds Awarded $1.5 Million SBIR Grant
Marketwire - Mon Jun 23, 6:01AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to announce that a research collaboration with Fox Chase Chemical Diversity Center ("FCCDC" (http://www.fc-cdci.com) has led to the award of a Phase 2B Small Business Innovation Research (SBIR) grant to FCCDC from the National Institute of Allergy and Infectious Disease (NIAID) of the National Institute of Health (NIH).

Autism - Pipeline Review, H1 2014 - 20 Companies & 42 Drug Profiles
M2 - Fri Jun 20, 2:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ltzhjv/autism_pipeline) has announced the addition of the "Autism - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Autism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Autism and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Dainippon Sumitomo Pharma Co., Ltd. - Novartis AG - Merz Pharma GmbH & Co. KgaA - Teva Pharmaceutical Industries Limited - Avanir Pharmaceuticals, Inc. - Snowdon Inc. - Curemark, LLC - Coronado Biosciences, Inc. - Omeros Corporation - Intra-Cellular Therapies, Inc. - Cellceutix Corporation - Heptares Therapeutics Ltd. - Otsuka Holdings Co., Ltd. - Reviva Pharmaceuticals Inc. - Naurex, Inc. - Nectid, Inc. - Mnemosyne Pharmaceuticals, Inc. - BioCrea GmbH - Saniona AB Drug Profiles - CM-AT - lurasidone hydrochloride - aripiprazole - cycloserine - fluoxetine - oxytocin - oxytocin - memantine hydrochloride - TSO - pioglitazone hydrochloride - oxytocin - oxytocin - (dextromethorphan hydrobromide quinidine sulfate) - oxytocin - oxytocin - RG-7314 - fluoxetine - fluoxetine - argipressin tannate - NU-211-01 NC-215-01 - Autologous Hematopoietic Stem Cells - glatiramer acetate - ITI-007 - Stem Cell Therapy for Central Nervous System Disorders - KM-391 - Program For Neurological Disorders - STX-110 - CN-2097 - acamprosate calcium - Small Molecules to Inhibit PI3K for Autism and Fragile X Syndrome For more information visit http://www.researchandmarkets.com/research/lt...m_pipeline

Cellceutix Clinical Trial of Anti-Cancer Drug Kevetrin Entering Eighth Cohort
Marketwire - Mon Jun 16, 6:01AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to report that the safety committee overseeing the Phase 1 clinical trial evaluating Cellceutix's lead anti-cancer drug Kevetrin for solid tumors being conducted at Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center has approved dosing for the eighth cohort. The dosing was been increased approximately 33 percent from the seventh cohort to 215 mg/m2. Enrollment for the eighth cohort is expected to commence shortly.

Cellceutix Completes Patient Enrollment in Clinical Trial of Prurisol
Marketwire - Mon Jun 02, 6:01AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, reports today that patient enrollment has been completed in the Company's Phase 1 crossover study of its anti-psoriasis drug candidate Prurisol. Cellceutix expects lab results, pharmacokinetic studies, and analysis to take approximately two months. If the data shows bioequivalence of Prurisol with Abacavir Sulfate, the Company will then schedule a meeting with the U.S. Food and Drug Administration regarding initiating a Phase 2/3 trial of Prurisol through the 505(b)(2) regulatory pathway.

Osteoarthritis - Pipeline Review, H1 2014: Includes 50 Company Profiles
M2 - Thu May 29, 3:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/j5kb3t/osteoarthritis) has announced the addition of the "Osteoarthritis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Osteoarthritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Osteoarthritis and special features on late-stage and discontinued projects. The report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team. Scope - The report provides a snapshot of the global therapeutic landscape of Osteoarthritis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Osteoarthritis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Osteoarthritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Mentioned: - A. Menarini Industrie Farmaceutiche Riunite Srl - AbbVie Inc. - Abiogen Pharma S.p.A. - Ablynx NV - AcurePharma AB - Addex Therapeutics - Allinky Biopharma - Ampio Pharmaceuticals, Inc. - Amura Holdings Ltd. - Asahi Kasei Pharma Corp. - Asklepios BioPharmaceutical, Inc. - Astellas Pharma Inc. - Aurigene Discovery Technologies Limited - Biopharm GmbH - Bone Medical Limited - Calzada Limited - Can-Fite BioPharma Ltd. - Cellceutix Corporation - Cellular Biomedicine Group, Inc. - Chong Kun Dang Pharmaceutical Corp. - Chugai Pharmaceutical Co., Ltd. - CrystalGenomics, Inc. - Galapagos NV - Genequine Biotherapeutics GmbH - Janssen Biotech, Inc. - Jenrin Discovery, Inc. - Laila Pharmaceuticals Pvt. Ltd. - MediPost Co., Ltd. - Medivir AB - Merck KGaA For more information visit http://www.researchandmarkets.com/research/j5...oarthritis

Cellceutix Signs Material Transfer Agreements for Defensin Mimetic Compounds With Leading Universities
Marketwire - Tue May 27, 6:01AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to report that the Company has signed material transfer agreements for compounds in its defensin mimetics portfolio with major university laboratories located in New York and New Jersey. These laboratories do significant government work and have expertise in anti-infective, anti-fungal and bio-defense applications. Cellceutix will be shipping the compounds to the university laboratories in the coming weeks. It is hoped that these collaborations will result in government assistance in developing the Company's novel compounds for a broad spectrum of indications.

Global Squamous Cell Carcinoma Therapeutics Pipeline Review 2014
M2 - Tue May 20, 9:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/72tfpz/squamous_cell) has announced the addition of the "Squamous Cell Carcinoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Squamous Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Squamous Cell Carcinoma and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Squamous Cell Carcinoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Squamous Cell Carcinoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Squamous Cell Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Squamous Cell Carcinoma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Boehringer Ingelheim GmbH - Novartis AG - Genmab A/S - Celgene Corporation - Clinuvel Pharmaceuticals Limited - Oncolytics Biotech Inc. - Oryzon Genomics S.A. - Hutchison MediPharma Limited - Merrimack Pharmaceuticals, Inc. - Neotropix, Inc. - Axelar AB - Onconova Therapeutics, Inc. - Omeros Corporation - Cellceutix Corporation - Cannabis Science, Inc. - Oncovir, Inc. - Genextra S.p.a. - Bexion Pharmaceuticals, LLC. - AbbVie Inc. Drug Profiles - afatinib - paclitaxel albumin-bound - AXL-1717 - pelareorep - rigosertib sodium - afamelanotide - boanmycin hydrochloride [docetaxel] - CIGB-128 - DAC-0060 - Poly-ICLC - BYL-719 - LJM-716 - interleukin-15 - Antibody Drug Conjugate for Squamous Cell Tumor - irinotecan sucrosofate liposomal - Kevetrin - CUV-9900 - BXQ-350 - CS-TATI-1 - CS-S/BCC-1 - TF-011-Monomethyl Auristatin E - AMXT-1501 eflornithine - Allogenic Mesenchymal Stem Cells - HMPL-453 - NTX-500 - GPR87 Antagonist for Cancer - GPR39 Antagonist for Esophageal Squamous Cell Carcinoma and Obesity-Related Type-2 Diabetes - Monoclonal Antibody For Squamous Cell Cancer - Drugs for Cutaneous Squamous Cell Carcinoma (cSCC) For more information visit http://www.researchandmarkets.com/research/72...amous_cell

Cellceutix Comments on Positive FDA Advisory Vote for Dalbavancin and Tedizolid
Marketwire - Tue Apr 01, 7:04AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company" is pleased to comment to its shareholders on yesterday's exciting regulatory developments and how it impacts Cellceutix's drug, Brilacidin.

Cellceutix Reports 20 Percent Enrollment Completed in Phase 2b Trial of Brilacidin as Short-Course Therapy for ABSSSI
Marketwire - Mon Mar 31, 8:25AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to provide shareholders an update on the status of the Company's clinical trial of its novel antibiotic Brilacidin as a treatment for Acute Bacterial Skin and Skin Structure Infections (ABSSSI). One month into the study, the trial has completed enrollment of approximately 20 percent of the total patients scheduled in the protocol.

Cellceutix Initiates Clinical Trial of Prurisol as New Treatment for Psoriasis
Marketwire - Tue Mar 25, 5:01AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to announce the initiation of the Company's clinical trial of its oral, small molecule drug candidate Prurisol(TM) for the treatment of psoriasis. The Prurisol(TM) tablets have been delivered to the clinical site in Miami, Florida and screening of subjects can now begin with the first dosing expected in the coming days.

Cellceutix to Initiate Psoriasis Clinical Trial
Marketwire - Fri Mar 21, 5:00AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, announces today that the U.S. Food and Drug Administration's ("FDA" 30-day waiting period pertaining to the Company's Investigational New Drug Application ("IND" for Prurisol(TM) has now passed. Cellceutix is moving towards the commencement of clinical trials of Prurisol(TM) as a new drug candidate for the treatment of psoriasis.

Seventh Cohort Underway in Cellceutix Clinical Trial of Kevetrin for Solid Tumors
Marketwire - Wed Mar 19, 7:42AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, announces today that the seventh cohort is now in progress in the Company's ongoing Phase 1 clinical trial of Kevetrin(TM), Cellceutix's novel anti-cancer drug candidate.

Cellceutix Reports 14 Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Patients Treated in Phase 2b Clinical Trial
Marketwire - Mon Mar 10, 5:01AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, announces today that through March 7 a total of 14 patients have been treated in the Company's Phase 2b clinical (7% of the 200 patients to be treated). The multi-center study is evaluating the safety and efficacy of Brilacidin as a novel antibiotic drug candidate as compared to daptomycin for the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI). Patients are receiving one of three different dosing regimens of Brilacidin (one of two single-dose regimens or one 3-day regimen) or a 7-day regimen of daptomycin. Cellceutix is pleased with the initial enrollment pace and believes that it will continue to escalate as the trial moves forward.

Cellceutix Expands to Gram-Negative Bacterial Infections
Marketwire - Wed Mar 05, 5:00AM CST
Cellceutix Corporation (OTCQB: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to inform shareholders that several preclinical investigations are underway with several lead compounds in animal models of Gram-negative bacterial infections. The Company is focusing this research on some of the most difficult to treat multi-drug resistant or "pandrug-resistant" bacterium where there is a significant and growing medical need for new therapies.

Cellceutix Enrolls First Patients in Phase 2b ABSSSI Clinical Trial
Marketwire - Wed Feb 26, 5:00AM CST
Cellceutix Corporation (OTCQB: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, announces today that the first patients have been enrolled and treated in the Company's Phase 2b clinical trial of Brilacidin in patients with Acute Bacterial Skin and Skin Structure Infection (ABSSSI).

Cellceutix Selects Dr. Reddy's Laboratories for Formulation of Brilacidin for Ophthalmic and Otitis Infections
Marketwire - Mon Feb 24, 6:01AM CST
Cellceutix Corporation (OTCQB: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, announces today that the Company has concluded negotiations with formulation developers and selected Dr. Reddy's Custom Pharmaceutical Services (CPS), part of the Pharmaceutical Services and Active Ingredients (PSAI) business unit of Dr. Reddy's Laboratories Ltd. ("Dr. Reddy's" , a New York Stock Exchange-listed company traded under the ticker "RDY", for the formulation of the Company's defensin mimetic drug Brilacidin for use in ophthalmic and otitis infections.

Cellceutix Submits Investigational New Drug Application (IND) for Clinical Trial of New Anti-Psoriasis Drug, Enrollment Underway in Phase 2b Clinical Trials of Brilacidin
Marketwire - Tue Feb 18, 6:01AM CST
Cellceutix Corporation (OTCQB: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, announces today that the Company has submitted an Investigational New Drug Application ("IND" to the U.S. Food and Drug Administration ("FDA" for the clinical development of Prurisol as a potential new treatment for psoriasis.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Finzly Welcomes Paul Finch to Drive BankOS Growth

Updated Category News Views 42

Finzly's Strategic Move to Boost Innovation Alright, folks, it seems Finzly means business. They just roped in Paul Finch, the brains who gave us Zelle during his stint as CEO over at Early Warning Services. This guy's been around the block with a couple of the biggest names in banking, and if his past headlines are any indicator, he's got the knack for shaking things up...

Continue Reading
Concierto's Azure Push Puts Sovereignty on Display

Updated Category News Views 78

Sovereignty has become the corporate cloud world's favorite hard-edged word. Concierto is taking that word straight onto the Microsoft Ignite 2026 floor, and frankly, it is a sensible place to make the case. The company, part of Trianz, will appear as a Gamechanger Sponsor from November 17 through 20 at San Francisco's Moscone Center, showing its platform at Booth #5435....

Continue Reading
Thoughts Unleashed Arrives With a Personal American Voice

Updated Category News Views 114

A lifetime of observation finally gets its own page Forty is an unusual age to begin writing poetry, which is exactly why Joyce Ann Grooms McGeehan's debut has a little more texture than the usual polished promise of inspiration. Thoughts Unleashed by an Independent, American Woman comes from someone who spent decades teaching French, English, and ESL, then retired to a...

Continue Reading
Red Cat Stock Drama: Revenue Targets and Legal Waves

Updated Category News Views 110

Red Cat's Revenue Predictions Crash and Burn Sitting there on August 6, 2026, Red Cat Holdings had everyone believing they were on a fast track to hitting a hefty revenue target: $150–$180 million for FY2026. CEO Jeffrey Thompson didn't mince words, boasting confidence like a captain before a storm. Fast forward three months, and they're waving the white flag, tossing...

Continue Reading
ZTO's Pricing Muscle Shows Up in Third-Quarter Results

Updated Category News Views 136

Ten billion parcels can hide plenty of ugly economics, but ZTO's third quarter does not look like a volume-at-any-cost stunt. The company moved 10.241 billion parcels, up 7.0% from a year earlier, and says that outpaced the industry by 4.1 percentage points. More importantly, revenue climbed 21.0% to RMB14.36 billion while adjusted net income reached RMB2.57 billion. That...

Continue Reading
Onward Therapeutics Secures $28M to Bolster Oncology R&D

Updated Category News Views 76

Cashing In to Conquer Cancer In the risk-laden world of biotech, Onward Therapeutics has just bagged a hefty NT$900 million—roughly US$28 million—from its Series B financing. That's not pocket change and speaks to the level of confidence their backers have, even as they plant their global headquarters firmly in Taipei since relocating from Switzerland. A Deep Dive...

Continue Reading
Snowhawk Enters Telarus as Digital Demand Gets Serious

Updated Category News Views 68

Telarus just pulled another serious capital partner into the room, and that matters more than the usual law-firm victory lap. Snowhawk Partners has invested in the technology services distributor alongside Columbia Capital, which remains a long-standing partner. Nobody disclosed a valuation, ownership percentage, financing mix, or closing date. Annoying? Sure. But the...

Continue Reading
A Decade of Giving: Light the World Initiative's Impact

Updated Category News Views 80

The Red Kiosk Revolution It's not every day that a church initiative pops up in global conversations, but here we are—ten years into the Light the World initiative by The Church of Jesus Christ of Latter-day Saints. What's interesting is how these little kiosks, like silent ambassadors, have become a staple in 145 spots this holiday season, spanning continents. Each...

Continue Reading
Caracal’s $200K VMI Pledge Targets Cadet Affordability

Updated Category News Views 160

A tuition award can still leave a brutal hole in the budget. That is the plain fact sitting underneath Caracal Products & Services’ $200,000 commitment to Virginia Military Institute. Federal ROTC scholarships can cover tuition, but VMI says room, board and quartermaster fees average about $15,000 annually. For a student who has done everything right—earned the ROTC...

Continue Reading
Spruce Spins Adrenyx En Route to Nasdaq in 2027

Updated Category News Views 114

New Frontiers: Adrenyx Biosciences Takes Shape Well, here's a new chapter in biotech drama. Spruce Biosciences, a name you might have tangled with if you're into tickers like NASDAQ:SPRB, just carved out a niche with the birth of Adrenyx Biosciences. The play? A separate company eyeing the endocrinology space, setting its sights on tackling congenital adrenal hyperplasia...

Continue Reading

Top 5 Most Recently Viewed Articles

Important Update for Investors in Metagenomi Class Action

Updated Category News Views 103

Key Deadline for Metagenomi Investors As investors in Metagenomi, Inc. keep a close watch, an important deadline is approaching. The time to file a lead plaintiff motion in the class action lawsuit is set for November 25, 2024. This action is vital for those who purchased or acquired Metagenomi securities, specifically those linked to the company’s latest initial public...

Continue Reading
Structure Therapeutics Engages with Investors at Key Conferences

Updated Category News Views 78

Structure Therapeutics Engages with Investors at Key Conferences Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company, is gearing up to participate in important investor conferences this September. The company is dedicated to developing innovative oral small molecule therapeutics aimed at treating metabolic and cardiopulmonary...

Continue Reading
OmaSp Reports Solid Financial Performance with Growth Prospects

Updated Category News Views 156

OmaSp's Strong Financial Performance and Future Outlook OMA SAVINGS BANK PLC has recently released its financial statements for the year ending December 31, 2024, showing promising results and projections for continued growth. Known as OmaSp, the bank reported a noteworthy fourth quarter, aligning with the expectations set forth at the beginning of the year, and a solid...

Continue Reading
Unveiling the Reagan National Economic Forum for Future Growth

Updated Category News Views 485

Reagan National Economic Forum Set to Inspire Economic Solutions The Ronald Reagan Presidential Foundation and Institute is gearing up for a transformative inaugural economic summit with leading figures from the business and economic policy landscapes to take place in late May 2025. About the Forum’s Objectives The Reagan National Economic Forum (RNEF) aims to provide a...

Continue Reading
Experience the Vibrant Latin Business Networking Event of 2025

Updated Category News Views 279

Celebrating the Latino Business Community Prepare yourself for an unforgettable networking event dedicated to the Latino business community, brought to you by Latin Biz Today and Mercy University. The Spectrum of Success event promises a night filled with excitement, learning, and cultural experiences that will leave a lasting impression on everyone involved. A Night of...

Continue Reading